Product
JS026/placebo
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic Profiles, and Immunogenicity of JS026 and JS026 in Together With JS016 Administered Intravenously to Healthy Chinese SubjectsStatus: Completed, Estimated PCD: 2022-12-08